$CNO

Tarasi Rocco F. III sold $97K of CNO

Tarasi Rocco F. III (Chief Marketing Officer) sold 1,891 shares of CNO Financial Group, Inc. (CNO) at $51.31 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tarasi Rocco F. III
Published Jul 1, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 1, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CNO
Neutral
high confidence
Mentioned
$CNO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CNONeutralLow
01

Why it matters

The disclosed event is an open-market sale by the CMO under a pre-arranged 10b5-1 plan; it is not a guidance, earnings, or regulatory update.

02

Market read

Traders may treat this as low-signal information; it mainly updates the insider activity record for CNO.

03

What to watch

The article provides only the sale details; it does not state whether other insiders bought, whether there were concurrent corporate events, or whether the plan size/timing is unusual.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-01 (after-hours) for an insider sale dated 2026-07-01.

Background

The article is an SEC Form 4 insider transaction for CNO Financial Group, filed on 2026-07-01.

Company-level read

Ticker impact

$CNONeutralHigh confidence
Context

CNO Financial Group insider Tarasi Rocco F. III sold 1,891 shares on 2026-07-01 at $51.31 via a 10b5-1 plan, per Form 4.

Expected impact

Minimal near-term impact; any effect is likely noise unless paired with other disclosures.

Evidence & confidence

The filing is a Form 4 open-market sale under a pre-arranged 10b5-1 plan, with no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with private concerns; traders may still monitor for follow-on insider buys or changes in sale patterns.

Key entities

  • CNO Financial Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tarasi Rocco F. III

    Chief Marketing Officer who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CNOMed

CNO Financial Group (CNO) Beats In Q2 But Is The Rally Already Priced In

CNO Financial Group (CNO) reported Q2 revenue beating expectations, with operating earnings per share up 45% and 16 consecutive quarters of sales growth. The stock is up 30.19% year-to-date and 42.14% over one year. However, it is slightly overvalued according to a narrative fair value of $53.50. Growth is driven by annuity and life/health policy sales, digital channels, and an aging U.S. population. Risks include low long-term interest rates and rising long-term care claims.

$CNOMed

California Nanotechnologies Posts 28% Revenue Growth in Q1 FY2027 as Nuclear Pivot Takes Hold

California Nanotechnologies (TSXV:CNO) reported Q1 FY2027 revenue of $917,854, up 28% from $716,553 a year earlier, for the quarter ended May 31, 2026. Adjusted EBITDA loss narrowed to $129,031 from $152,707, while net loss was $449,598. The company attributes growth to customer diversification and a nuclear supply-chain pivot tied to initial SMR component purchase orders.

$CNOHighAI 9/10

CNO Financial (CNO) Q2 2026 Earnings Call Transcript

CNO Financial Group (NYSE:CNO) reported Q2 2026 operating EPS of $1.26, up 45% year over year, and net operating income of $119.5 million. Total new annualized premiums rose 7% to a record. Full-year EPS guidance was raised to $4.60 to $4.80. The company also repurchased $60 million of shares.

$CNOMed

CNO Financial posts insurance income gain on 16-quarter sales streak

CNO Financial Group reported Q2 2026 sales growth for a 16th consecutive quarter. Insurance policy income rose to $680.7 million from $651.3 million a year earlier, and net income increased to $125.9 million, or $1.33 per diluted share, from $91.8 million, or $0.91. CNO raised full-year 2026 operating EPS guidance by 8% at the midpoint and estimated RBC at 377% as of June 30.

$CNOMed

CNO Financial Group’s (NYSE:CNO) Q2 CY2026 Sales Beat Estimates

Insurance services company CNO Financial Group (NYSE: CNO) announced better-than-expected revenue in Q2 CY2026, with sales up 34.6% year on year to $1.29 billion. Its GAAP profit of $1.33 per share was 36.4% above analysts’ consensus estimates. Is now the time to buy CNO Financial Group? Find out by accessing our full research report, it’s free.

$CNOLow

CNO Financial Group, Inc. (CNO): Results of Operations and Financial Condition

CNO Financial Group, Inc. (CNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. News For Immediate Release CNO Financial Group Reports Second Quarter 2026 Results Carmel, Ind., July 30, 2026 - CNO Financial Group, Inc. (NYSE: CNO) today reported its second quarter 2026 financial results: • Strong execution and momentum continues; Raising 2026 operating earni